XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Stockholders' Equity (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Stockholders' Equity Note [Abstract] |
Schedule of Common Stock Reserved for Future Issuances | As of June 30, 2024, the Company had reserved Common Stock for future issuances as follows:
| June 30, 2024 |
Common stock reserved for Contingent Earnout Shares | 15,000,000 |  |
Common stock reserved for Option Agreement | 1,333,334 |  | (1)
Exercise of options outstanding under stock plans | 12,521,655 |  |
Options available for issuance under stock plans | 5,809,549 |  |
Shares available for grant under ESPP | 1,030,033 |  |
Warrants to purchase Common Stock | 5,588,506 |  |
| 41,283,077 |  |
___________________________ (1)Assumes the exercise of the entire Option as provided for in the Option Agreement at the minimum purchase price of $7.50 per share.
Schedule of Common Stock Warrants Outstanding | The Company had the following Common Stock warrants outstanding as of June 30, 2024 and December 31, 2023:
| Common Stock Warrants Outstanding
Legacy Humacyte Common Stock Warrants | 411,006 |
Private Placement Warrants | 177,500 |
Public Warrants | 5,000,000 |
Total Common Stock Warrants | 5,588,506 |
Schedule of Assumptions Used in the Valuations | The Private Placement Warrants were valued using the following assumptions under the Monte Carlo simulation value model:
| June 30, 2024 |  | December 31, 2023
Market price of public stock | $ | 4.80 |  | $ | 2.84
Exercise price | $ | 11.50 |  | $ | 11.50
Expected term (years) | 2.16 |  | 2.65
Expected share price volatility | 96.0 | % |  | 75.0 | %
Risk-free interest rate | 4.68 | % |  | 4.09 | %
Estimated dividend yield | 0 | % |  | 0 | %
Assumptions used in the valuations are described below:
| June 30, 2024 |  | December 31, 2023
Current stock price | $ | 4.80 |  | $ | 2.84
Expected share price volatility | 88.6 | % |  | 86.7 | %
Risk-free interest rate | 4.36 | % |  | 3.88 | %
Estimated dividend yield | 0 | % |  | 0 | %
Expected term (years) | 10.00 |  | 10.00

X
- Definition The tabular disclosure of common stock were reserved for future issuance. + References No definition available. + Details
Name: | huma_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
Namespace Prefix: | huma_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration